NCT00904722 - Monoclonal Antibody CT-011 in Combination With Rituximab in Patients With Relapsed Follicular Lymphoma | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

January 31, 2010

Primary Completion Date

April 30, 2015

Study Completion Date

April 30, 2015

Conditions

Lymphoma

Interventions

DRUG

CT-011

Administered intravenously at a dose of 3.0 mg/kg on days 1, 29 (+/- 7 days), 57 (+/- 7 days), and 85 (+/- 7 days).

DRUG

Rituximab

Administered intravenously at the standard dose of 375 mg/m\^2 weekly for 4 weeks on days 17 (+/- 1 day), 24 (+/- 1 day), 31 (+/- 1 day), and 38 (+/- 1 day).

Trial Locations (1)

77030

University of Texas MD Anderson Cancer Center, Houston